New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver

The nutraceutical Superba Krill Oil, rich in omega-3 phospholipids, according to a new rat preclinical study performed for the biotechnological company Aker BioMarine, gives substantially more reduction of fat in the heart and the liver than omega-3 from fish oil supporting its ability to contribute to heart health and normal liver function.

The study has been performed by internationally acknowledged research groups in Italy. Under supervision by Dr. Sebastiano Banni and Dr. Vincenzo Di Marzo, the effect of Superba Krill Oil and omega-3 fish oil was investigated in obese zucker rats.

- It is very interesting that Superba Krill Oil has a significantly better effect than fish oil, says Dr. Banni.

On parameters associated with obesity, Superba Krill Oil reduced the fat content in the heart by 42%. Fish oil reduced the fat content by 2%. A high level of fat in the heart is non-beneficial for the heart function, and it is therefore important to promote a normal level of fat content in the heart.

The corresponding examination of the fat amount in liver showed a reduction of 60% after administration of Superba Krill Oil, while fish oil reduced the fat content in the liver by 38%. A high level of fat in the liver impairs liver function. This can lead to a reduced insulin sensitivity and contribute to blood sugar management issues/concerns.

Sebastiano Banni and Vincenzo Di Marzo have through many years been leading on their respective research fields and have published several articles in high standard international journals.

- Aker BioMarine has in this study documented the effects of Superba Krill Oil in cooperation with two of the world-leading research groups within this special field. We are proud to cooperate with highly experienced researchers to document the beneficial effects of Superba Krill Oil, says M.D. Hogne Vik, EVP, Documentation, Aker BioMarine.

The study is published in Journal of Nutrition, Volume 139, Number 8, August 2009, and is available at

For more information, please contact:
M.D. Hogne Vik, EVP, Documentation, Aker BioMarine, cell phone: +47 975 35 326

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.